267. 高IgD症候群 Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 11 / 薬物数 : 6 - (DrugBank : 1) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 44
薬物ごとの開発者(Primary Sponsor)、臨床試験情報(抜粋)です。
ACZ885
Novartis Farma SpA
2014 Phase 3 EUCTR2013-004291-35-IT Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
Novartis Farmacéutica, S.A.
2014 Phase 3 EUCTR2013-004291-35-ES Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
Novartis Pharma Services AG
2014 Phase 3 EUCTR2013-004291-35-NL Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004291-35-IE Belgium;Canada;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004291-35-HU Belgium;Canada;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004291-35-GR Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004291-35-BE Belgium;Canada;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
ACZ885, 150mg/1.0ml
Novartis Pharma Services AG
2014 Phase 3 EUCTR2013-004291-35-DE Belgium;Canada;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
Canakinumab
Novartis Pharmaceuticals
2011 Phase 2 NCT01303380 Spain;
ITF2357
Radboud University
2006 Phase 2 NCT00442182 Netherlands;
Ilaris
Novartis Farma SpA
2014 Phase 3 EUCTR2013-004291-35-IT Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
Novartis Farmacéutica, S.A.
2014 Phase 3 EUCTR2013-004291-35-ES Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
Novartis Pharma Services AG
2014 Phase 3 EUCTR2013-004291-35-NL Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004291-35-DE Belgium;Canada;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
Novartis pharma AG
- Phase 3 EUCTR2017-001678-40-Outside-EU/EEA Japan;
Novartis Farma SpA
2014 Phase 3 EUCTR2013-004291-35-IT Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
Novartis Farmacéutica, S.A.
2014 Phase 3 EUCTR2013-004291-35-ES Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
Novartis Pharma Services AG
2014 Phase 3 EUCTR2013-004291-35-NL Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004291-35-IE Belgium;Canada;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004291-35-HU Belgium;Canada;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004291-35-GR Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004291-35-BE Belgium;Canada;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
ACZ885, 150mg/1.0ml
Novartis Pharma Services AG
2014 Phase 3 EUCTR2013-004291-35-DE Belgium;Canada;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
Canakinumab
Novartis Pharmaceuticals
2011 Phase 2 NCT01303380 Spain;
ITF2357
Radboud University
2006 Phase 2 NCT00442182 Netherlands;
Ilaris
Novartis Farma SpA
2014 Phase 3 EUCTR2013-004291-35-IT Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
Novartis Farmacéutica, S.A.
2014 Phase 3 EUCTR2013-004291-35-ES Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
Novartis Pharma Services AG
2014 Phase 3 EUCTR2013-004291-35-NL Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004291-35-DE Belgium;Canada;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
Novartis pharma AG
- Phase 3 EUCTR2017-001678-40-Outside-EU/EEA Japan;